While global M&A deal value across sectors remained relatively flat overall, pharmaceuticals and life sciences M&A in 2024 dipped relative to the prior year. This stands in stark contrast to 2023, when life sciences M&A outperformed the market with a 50% increase in deal value from 2022 compared to a 17% decline in overall M&A activity across all industries. Luckily, there’s more to this year’s story. The number of deals in the sector in 2024 was actually down only slightly from the prior year, at a 5.2% decline. Total deal value is where the market really shed its weight – down a remarkable 33.7% from 2023. Clearly, deals have been getting done in the sector – life sciences buyers are still eating about as many meals, they’re just smaller bites.
Read the full article: 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025? //
Source: https://www.lexology.com/library/detail.aspx?g=aaa3a48f-e942-40e7-92aa-1647c276c73a